Artificial intelligence has shown promise in helping doctors predict which patients may be susceptible to chronic diseases like Alzheimer's.
But despite the rapid advances, the healthcare industry is still in the early days of rolling out AI-powered treatments and drugs, Morten Sogaard, Pfizer's vice president and head of genome sciences and technologies, said at Fortune'sBrainstorm Health conference in San Diego on Wednesday.
